Biovica International AB Q4 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jakob Lembke - ABG Sundal Collier Introduce - Analyst : This is Jakob Lembke at ABG. I have a few questions. And my first question is on the CLIA certification of the lab just on the timing there, if you assess that it will be in place before or when you get a potential clearance you can start to sell in Q4?

Question: Jakob Lembke - ABG Sundal Collier Introduce - Analyst : Okay. And just to understand... REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 16, 2022 / 1:00PM, BIOVICb.ST - Q4 2022 Biovica International AB Earnings Call

Question: Jakob Lembke - ABG Sundal Collier Introduce - Analyst : Yes, that was going to be my follow-up, if there's any material, like moving parts or if it's more straightforward.

Question: Jakob Lembke - ABG Sundal Collier Introduce - Analyst : Okay. Sounds good. My second question is on the costs, and the personnel costs seem to be a bit higher in the quarter. And I think you ended the year at 25 employees and now also when you're looking to recruit the U.S. salesforce, just how should we think about costs and maybe the increase to head count going forward?

Question: Jakob Lembke - ABG Sundal Collier Introduce - Analyst : Okay. And just lastly, I mean on the more data you talked about here today during the presentation and the publications you have had recently. Just looking at it, sort of what are, I guess, the results and conclusions to draw? How do you go forward to sort of position the test to provide value to the market and the clinic?